Complete titration schedules for semaglutide and tirzepatide, with guidance on when to push forward, when to slow down, and how to get the most from your therapy.
Quick Summary: Proper titration is one of the most important factors in GLP-1 success. Going too fast causes unnecessary side effects; going too slow delays results. This guide covers the standard titration schedules used in clinical practice, what "maximum tolerated dose" actually means, injection technique, and the evidence around micro-dosing protocols. Always confirm your dosing plan with your prescribing provider.
GLP-1 receptor agonists don't work like antibiotics where you take a fixed dose and you're done. They're titration-based medications — meaning you start low and gradually increase the dose over months, allowing your body to adapt. Skipping this ramp-up is one of the most common mistakes that leads people to abandon therapy early due to side effects.
The gastrointestinal side effects associated with GLP-1s — nausea, vomiting, constipation, diarrhea — are almost entirely dose-dependent. They're most pronounced during and immediately after dose increases. When patients follow proper titration, most find side effects are manageable and temporary. When they rush, they get hit hard unnecessarily.
Understanding the titration schedule your provider has prescribed, and knowing how to navigate it, is genuinely one of the most important tools you have for a successful outcome.
The standard titration schedule for subcutaneous semaglutide — whether branded Wegovy or compounded — follows the protocol established in the STEP clinical trials and approved in Wegovy's prescribing information. For compounded semaglutide, most reputable providers follow the same schedule.
| Period | Weeks | Dose | Notes |
|---|---|---|---|
| Phase 1 | Weeks 1–4 | 0.25 mg/week | Initiation dose. Not a therapeutic dose — tolerance building only. |
| Phase 2 | Weeks 5–8 | 0.5 mg/week | First therapeutic dose. Most patients begin seeing appetite suppression here. |
| Phase 3 | Weeks 9–12 | 1.0 mg/week | Increased efficacy. Some patients stay here long-term if tolerating well and responding. |
| Phase 4 | Weeks 13–16 | 1.7 mg/week | Intermediate dose. Used in some protocols as a stepping stone to 2.4mg. |
| Phase 5 | Week 17+ | 2.4 mg/week | Maximum approved dose for weight management (Wegovy). Highest efficacy tier. |
Source: Wegovy (semaglutide) Prescribing Information, Novo Nordisk. Compounded protocols may vary — confirm with your provider.
Not everyone reaches 2.4mg. Some patients find an effective, tolerable dose at 0.5mg or 1.0mg and there's no clinical requirement to push higher if you're achieving meaningful results at a lower dose. More on this below.
Tirzepatide's titration is more granular — six dose levels versus five for semaglutide — and the intervals are typically 4 weeks between increases. This longer ramp-up reflects tirzepatide's dual GIP + GLP-1 mechanism and the generally stronger GI effects during initial titration for some patients.
| Period | Weeks | Dose | Notes |
|---|---|---|---|
| Phase 1 | Weeks 1–4 | 2.5 mg/week | Initiation dose. Tolerance building only — not a therapeutic dose. |
| Phase 2 | Weeks 5–8 | 5 mg/week | First therapeutic dose. Significant appetite suppression begins for most patients. |
| Phase 3 | Weeks 9–12 | 7.5 mg/week | Middle therapeutic range. Many patients find strong results here. |
| Phase 4 | Weeks 13–16 | 10 mg/week | Upper mid-range. Good balance of efficacy and tolerability for many. |
| Phase 5 | Weeks 17–20 | 12.5 mg/week | Near-maximum dose. Step toward highest efficacy tier. |
| Phase 6 | Week 21+ | 15 mg/week | Maximum approved dose (Zepbound/Mounjaro). Highest weight loss efficacy demonstrated in SURMOUNT trials. |
Source: Zepbound (tirzepatide) Prescribing Information, Eli Lilly. Compounded protocols may vary — confirm with your provider.
These providers include licensed physician oversight to customize your titration schedule based on your individual response and tolerability.
The schedules above represent the standard protocol — not a mandatory minimum pace. Your prescriber can and should extend any phase if you're experiencing significant side effects or struggling to tolerate a dose increase. In clinical practice, "slow titration" approaches are well-supported and often produce better long-term adherence.
Consider asking your provider about slowing down if you're experiencing:
Staying at a comfortable dose for an extra 4 weeks is almost always better than abandoning therapy. A slow titration that gets you to your target dose is far more valuable than a fast titration that causes you to quit at week 6.
In clinical pharmacology, "maximum tolerated dose" (MTD) refers to the highest dose a patient can receive without unacceptable side effects. For GLP-1 therapy, this concept is particularly relevant because weight loss outcomes are dose-dependent — higher doses generally produce more weight loss — but the relationship is not linear and the gap between doses is not always large.
The STEP 1 trial (semaglutide 2.4mg) demonstrated mean weight loss of approximately 14.9% body weight over 68 weeks. The STEP 2 trial at lower doses showed less weight loss, confirming the dose-response relationship. Similarly, the SURMOUNT-1 trial for tirzepatide showed 15mg producing approximately 20.9% mean weight loss versus 14.7% at 5mg — a meaningful difference, but not enormous.
Clinically, many patients find a "personal plateau dose" below the maximum — a dose at which they're losing weight at an acceptable rate, tolerating the medication well, and not experiencing disruptive side effects. Staying at that dose is reasonable and clinically appropriate. Pushing to the maximum dose purely for maximum weight loss is not always the right choice for every patient.
Discuss your goals and your tolerability with your provider. The right dose is the highest dose you can tolerate comfortably while achieving meaningful results — not necessarily the maximum dose on the label.
One of the most active discussions in the compounded GLP-1 community in 2025–2026 has been around "micro-dosing" — using doses significantly lower than standard therapeutic doses as a long-term maintenance strategy rather than a titration phase.
Proponents argue that very low doses (e.g., 0.1–0.25mg semaglutide weekly) can maintain appetite suppression and weight stability with minimal side effects and lower cost, once a patient has reached their goal weight. Some compounding pharmacies offer micro-dose vials specifically designed for this use case.
As of March 2026, there are no published RCTs validating micro-dosing as a maintenance strategy. The supporting evidence is observational — patient reports and prescriber experience. This doesn't make the approach wrong, but it means the data to confidently recommend or validate it doesn't yet exist.
Some endocrinologists and obesity medicine specialists use micro-dosing in clinical practice for carefully selected maintenance patients. Others prefer maintaining the last effective therapeutic dose. This is an area where your individual provider's experience and judgment matters a great deal, and where patient-specific factors should drive the decision.
Subcutaneous injection technique affects both drug absorption and local tolerability. Poor technique is a real source of unnecessary discomfort and potentially suboptimal absorption. The right approach is straightforward once you know it.
Best-practice injection technique for GLP-1 subcutaneous injections:
If you experience significant injection site reactions — prolonged redness, nodules, or pain — discuss this with your provider. These can sometimes indicate a technique issue, an allergic response to excipients in the formulation, or a need to adjust injection sites.
Care Bare Rx offers physician-supervised programs with individualized titration support.
Compare with Care Bare Rx →There are legitimate clinical reasons to switch from semaglutide to tirzepatide (or vice versa). This isn't a failure — it's clinical optimization. Reasons your provider might recommend a switch include:
When switching, there is typically a washout period consideration, and your new titration will usually restart from the beginning dose of the new drug. Your provider can guide the appropriate cross-titration protocol for your specific situation.
Weekly GLP-1 injections can be taken on any day of the week — what matters is consistency. Choose a day and stick to it. Many patients choose a day when they have more flexibility (weekends work well for many) because the 24–48 hours after an injection often involve the most noticeable side effects.
Time of day does not significantly affect efficacy or absorption for weekly injectables. Some patients find morning injections work better because side effects can include mild nausea, and being awake and active helps manage it. Others find evening injections mean side effects occur during sleep and they wake feeling fine. Try both and see what works for your body.
Food intake around injection time: the medication does not require fasting before or after. However, if you're experiencing nausea, avoiding large or fatty meals for a few hours around injection time may help.
GLP-1CompoundPharmacy.com content is produced by a research team with backgrounds in health journalism, clinical pharmacology, and patient advocacy. All clinical claims are sourced from peer-reviewed literature, FDA documents, or named clinical trials. We do not accept payment for editorial coverage. No Fluff. Just Sources.
Physician-supervised titration support